As mentioned above, CAXIIis, novel and strong anticancer agents, can enhance the therapeutic effect of PD-1 inhibitors by regulating the antitumor immunity in HCC (47), providing a new thought for cancer treatment. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.